Drugs / OP0201
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03828149 | Feb → Mar 2019 | — | Novus Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03766373 | Jan 2019 | otitis media | Novus Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03748758 | Nov 2018 → Mar 2019 | — | Novus Therapeutics, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03818815 | Feb 2019 → Mar 2020 | otitis media | Novus Therapeutics, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OP0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03766373 ↗ |
| Route | Intranasal | “when administered intranasally in healthy adults subjects” NCT03748758 ↗ |